SU16. Predictors of Treatment Response of Adjunct Minocycline to Clozapine in Refractory Schizophrenia

Background: Accumulating evidence suggests minocycline (MINO) is effective as an adjunct treatment in schizophrenia. We previously reported significant improvement in avolition, anxiety/depression and working memory and a trend for positive symptoms and total Brief Psychiatric Rating Scale (BPRS) scores with MINO in a double-blind, placebo-controlled trial. We also found a >30% reduction in total BPRS scores in 25% of the MINO group compared to 4% in placebo (P = .04). Here we examine variables associated with symptom improvements.